Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy / Radioterapia de rescate con reirradiación para el cáncer de próstata recurrente después de braquiterapia primaria de dosis baja
Clin. transl. oncol. (Print)
; 26(4): 872-879, Abr. 2024. ilus, graf
Artigo
em Inglês
| IBECS
| ID: ibc-VR-50
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Purpose:
Local recurrence of prostate cancer after low-dose rate brachytherapy is a clinical problem with limited salvage treatment options. This prospective study evaluated the tolerability and outcome of salvage external beam radiation therapy (S-EBRT) for locally recurrent prostate cancer after primary low-dose rate prostate brachytherapy (LDR-BT). Materials andmethods:
Between October 2012 and 2022, 18 patients with biopsy-proven locally recurrent prostate cancer after primary LDR-BT and received S-EBRT. We evaluated biochemical failure (BF), overall survival (OS) and acute/late gastrointestinal and urinary toxicities (CTCAE v5.0 or CTCAE v4, only before 2017).Results:
Median follow-up was 32 months (range, 5124). The median age was at S-EBRT 68 years (range 5979). 34% (6/18) were low risk, 44% (8/18) intermediate risk, 5% (1/18) high risk, and 17% (3/18) not specified. All patients were treated with IMRT/VMAT and received 60 Gy (2.5 Gy/fraction) to the prostate and 40% (7/18) 55.2 Gy (2,3 Gy/fx) to the seminal vesicles. 56% received ADT The 3-year OS and biochemical relapse-free survival after S-EBRT were 100% and 89%, respectively, with a median PSA nadir 0,035 ng/mL (0,010,34). Acute cystitis was present in 72% (13/18) of patients (27% of Grade > 2). Urethritis was present in 78% (14/18) patients (16% of cases Grade > 3), and acute rectitis occurred in 22% (4/18) of patients (no cases Grade > 3).Conclusions:
Our data suggest that the treatment of locally recurrent prostate cancer with S-EBRT could provide adequate disease control safely and be used as an additional treatment in the natural history of prostate cancer patients. However, the results are still early and the sample is small; larger studies with longer follow-up would be mandatory.(AU)
Buscar no Google
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Medicinas Complementares:
Homeopatia
Assunto principal:
Fragilidade
/
Ansiedade
/
Osteoporose
/
Percepção
/
Exame Físico
/
Neoplasias da Próstata
/
Radioterapia
/
Isolamento Social
/
Doenças Autoimunes
/
Espanha
Tipo de estudo:
Estudo diagnóstico
/
Estudo de etiologia
/
Guia de prática clínica
/
Estudo de incidência
/
Estudo observacional
/
Estudo de prevalência
/
Estudo prognóstico
/
Fatores de risco
/
Estudo de rastreamento
Limite:
Humanos
/
Feminino
/
Masculino
/
Idoso
/
Adolescente
/
Adulto
/
Criança
/
Recém-Nascido
País/Região como assunto:
Europa
Idioma:
Espanhol
/
Inglês
/
Português
Revista:
An. pediatr. (2003. Ed. impr.)
/
Asclepio
/
Clin. transl. oncol. (Print)
/
Gastroenterol. hepatol. (Ed. impr.)
/
Int. microbiol
/
Med. oral patol. oral cir. bucal (Internet)
/
Nutr. hosp
/
Radiología (Madr., Ed. impr.)
/
Reumatol. clín. (Barc.)
/
Rev. esp. anestesiol. reanim
Ano de publicação:
2023
/
2022
/
2024
/
2021
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complejo Hospitalario de Cartagena/España
/
Hangzhou Normal University/Peoples Republic of China
/
Hospital General de Granollers/España
/
Hospital Universitari Josep Trueta/España
/
Hospital Universitari Vall dHebron/España
/
Hospital Universitario Mútua de Terrassa/España
/
Hospital Universitario de Salamanca/España
/
Hospital Universitario y Politécnico La Fe/España
/
Hospital Álvaro Cunqueiro/España
/
Instituto de Investigación Biomédica de Salamanca/España
Similares
MEDLINE
...
LILACS
LIS